The Research Of Predictive Value Of Quantitative Detection Of HBsAg And HBeAg For HBeAg Seroconversion In CHB Patients Treated With PegIFN Alpha-2a

Objective The aim of this study was to investigate the correlation between the quantitative detection of HBsAg and HBeAg PegIFN a-2a treatment of CHB patients HBeAg seroconversion predictive value.Methods Continuous collection in October 2014 to May 2016 in yantai city infectious diseases hospital PegIFNα-2a antiviral treatment of 70 cases datum of HBeAg positive patients with CHB.Retrospective analysis of patients’baseline alanine aminotransferase(ALT)and HBVDNA loads,serological markers level and treatment after 4,8,12,weeks and every 12 weeks in patients with serum levels of ALT,HBVDNA load,serological markers.Observe Real-life world PegIFN a-2a treatment of HBeAg positive patients with CHB cumulative HBeAg serological conversion rate.HBeAg seroconversion cumulative incidence of kaplan meier-method,use Log-rank test to compare different baseline level of HBsAg and HBeAg influence factors of cumulative HBeAg seroconversion.The participants work curves(ROC)analysis is 4 weeks after treatment,8 weeks,12 weeks and 24 weeks,of HBsAg and HBeAg quantitative of HBeAg seroconversion predictive value.Results 1.There are 21 cases HBeAg Serological conversion from 70 patients.The serological conversion rate is 34.3%.2.The patients whose baseline HBsAg<1500IU/ml are more likely to happen HBeAg seroconversion than whose baseline HBsAg≥1500IU/ml,P<0.01,have statistical significance.The patients-whose baseline HBeAg<100S/CO are more likely to happen HBeAg seroconversion than whose baseline ≥100S/CO,P<0.01,have statistical significance.3.ROC curve analysis,according to the results of treatment at 24 weeks of HBsAg and HBeAg quantitative quantitative HBeAg seroconversion prediction value is significantly better than other index(The area under the ROC curve were 0.811 and 0.900 respectively).Conclusions The patients whose baseline HBsAg<1500IU/ml and<100S/CO are more likely to achieve seroconversion by PegIFN a-2a treatment of HBeAg positive patients with CHB.Therapy at 24 weeks of HBsAg and HBeAg quantitative level is PegIFN α-2a treatment effective predictors in patients with CHB.